These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 8118746

  • 1. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
    Kollerup G, Hermann AP, Brixen K, Lindblad BE, Mosekilde L, Sørensen OH.
    Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
    [Abstract] [Full Text] [Related]

  • 2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 3. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A.
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [Abstract] [Full Text] [Related]

  • 4. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 5. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 6. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
    Thamsborg G, Jensen JE, Kollerup G, Hauge EM, Melsen F, Sorensen OH.
    Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
    [Abstract] [Full Text] [Related]

  • 7. Prevention of postmenopausal bone loss by rectal calcitonin.
    Reginster JY, Jupsin I, Deroisy R, Biquet I, Franchimont N, Franchimont P.
    Calcif Tissue Int; 1995 Jun; 56(6):539-42. PubMed ID: 7648483
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C.
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [Abstract] [Full Text] [Related]

  • 9. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
    Overgaard K.
    Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
    [Abstract] [Full Text] [Related]

  • 10. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
    Gonnelli S, Cepollaro C, Montomoli M, Gennari L, Montagnani A, Palmieri R, Gennari C.
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
    [Abstract] [Full Text] [Related]

  • 11. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
    Nielsen NM, von der Recke P, Hansen MA, Overgaard K, Christiansen C.
    Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
    [Abstract] [Full Text] [Related]

  • 12. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D.
    Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
    [Abstract] [Full Text] [Related]

  • 13. Nasal calcitonin for treatment of established osteoporosis.
    Overgaard K, Riis BJ, Christiansen C, Pødenphant J, Johansen JS.
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
    [Abstract] [Full Text] [Related]

  • 14. Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis.
    Overgaard K, Hansen MA, Dirksen KL, Christiansen C.
    Calcif Tissue Int; 1992 Sep; 51(3):184-8. PubMed ID: 1422962
    [Abstract] [Full Text] [Related]

  • 15. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E.
    J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
    [Abstract] [Full Text] [Related]

  • 17. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC.
    Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
    [Abstract] [Full Text] [Related]

  • 18. [Synthetic salmon calcitonin suppositories for the short-term treatment of involutive osteoporosis].
    Isaia GC, Di Stefano M, Sciolla A, Mussetta M, Vassellatti D.
    Minerva Med; 1995 Mar; 86(3):101-4. PubMed ID: 7603605
    [Abstract] [Full Text] [Related]

  • 19. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
    Downs RW, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, Wang L, Smith ME, Gormley GJ, Melton ME.
    J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
    [Abstract] [Full Text] [Related]

  • 20. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L, Kohlmeier L, Kent K, Marcus R.
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.